

**Table 1. Characteristics of participants, stratified on ESBL-E carriage status**

	Total (n=352)	ESBL-E carriage status		<i>p</i>
		ESBL-positive (n=176)	ESBL-negative (n=176)	
Age, years <sup>*</sup>	33 (27-44)	33 (27-44)	34 (27-46)	0.43
Geographic origin				0.90
Europe	303 (86.1)	152 (86.4)	151 (85.8)	0.99
North America/DOM TOM/Australia	18 (5.1)	9 (5.1)	9 (5.1)	0.99
Africa/Middle East	31 (8.8)	15 (8.5)	16 (9.1)	0.99
Asia	0 (0)	0 (0)	0 (0)	0.99
Hospitalization in the past 12 months	15 (6)	5 (3.9)	10 (8.1)	0.51
Antibiotic use in the past 6 months	80 (22.7)	39 (22.2)	41 (23.3)	0.90
Travel outside of France	276 (78.4)	138 (78.4)	138 (78.4)	0.99
ESBL-E prevalence of region traveled <sup>#</sup>				
Low (<10%)	66 (18.8)	33 (18.8)	33 (18.8)	0.99
Moderate (10-25%)	129 (36.6)	64 (36.4)	65 (36.9)	0.99
High (>25%)	81 (23)	41 (23.3)	40 (22.7)	0.99
Gender				0.89
Male	293 (83.2)	147 (83.5)	146 (83.0)	
Female	59 (16.8)	29 (16.5)	30 (17)	
Sexual group				
HIV- MSM on PrEP	56 (15.9)	28 (15.9)	28 (15.9)	0.99
HIV- MSM not on PrEP	62 (17.6)	31 (17.6)	31 (17.6)	0.99
HIV+ MSM	99 (28.1)	50 (28.4)	49 (27.8)	0.99
HIV- MSW	76 (21.6)	38 (21.6)	38 (21.6)	0.99
HIV- WSM	59 (16.8)	29 (16.5)	30 (17)	0.99
Sexual activity in the past 6 months				

Number of stable partners <sup>‡</sup>	1 (0-1)	1 (0-1)	1 (0-1)	0.22
Number of casual partners <sup>‡</sup>	4 (1-12)	4 (1-12)	4 (0-12)	0.76
Number of unknown casual partners <sup>‡</sup>	1 (0-10)	1 (0-10)	1 (0-10)	0.89

Frequencies (%) are provided for each variable; except for variables with (\*) for which the median (interquartile range) is given.

Statistical comparisons were made using McNemar test for categorical variables and Wilcoxon Signed-Rank test for continuous variables.

<sup>‡</sup>For those who traveled to a country outside of France.

Abbreviations: DOM, *département outre mer*; TOM, *territoire outre mer*; ESBL-E, extended spectrum  $\beta$ -lactamase-producing *Enterobacteriaceae*; HIV, human immunodeficiency virus; MSM, men who have sex with men; MSW, men who have sex with exclusively women; PrEP, pre-exposure prophylaxis for HIV.